The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.10
Bid: 44.10
Ask: 45.90
Change: 0.00 (0.00%)
Spread: 1.80 (4.082%)
Open: 44.10
High: 44.10
Low: 44.10
Prev. Close: 45.00
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of breakthrough purification system

16 Aug 2017 07:00

RNS Number : 0944O
Benchmark Holdings PLC
16 August 2017
 

 

Benchmark Holdings plc("Benchmark" or the "Company")

 

Benchmark pioneers environmentally benign purification system in the fight against sealice

 

Benchmark is pleased to announce it has developed a major industry breakthrough for the salmon industry, CleanTreat, a new fully contained purification system. Chemical based bath treatments that are released into water are one of the biggest objections to the salmon farming industry and CleanTreat works to solve this environmental challenge.

 

CleanTreat ensures the safe use of compounds in the marine environment by purifying the medicine from the treatment water to undetectable levels. The CleanTreat system is the first of its kind to be used in aquaculture, and will be administered in conjunction with Benchmark's next generation sealice treatment, which is currently in late stage development. The system can also be used with most licensed bath treatments.

 

CleanTreat is packaged in a standard ISO shipping container which allows for modular installation on board well-boats, treatment barges and land based systems. The system ensures that treatment water is purified and detached lice will be filtered and collected, achieving the highest level of environmental safety and also reducing the risk of future development of resistance.

 

The treatment plan will firstly be launched in the Norwegian market. The trials will see leading producers pilot the new system and product at commercial scale. The worldwide market for salmon is estimated to be worth 10.7bn USD per annum and the estimated cost of sealice for the global market is estimated to be 1bn USD.

 

Malcolm Pye, CEO of Benchmark commented:

"Sea lice are a major challenge for the sustainable growth of the salmon industry. Our main objective as a company is to produce innovative treatments which ensure the good health and welfare of farmed fish, that are highly efficacious and have no significant impact on the environment."

 

"The Benchmark Group has a growing toolkit of products and services, such as CleanTreat, alongside the launch in 2015 of sealice resistant salmon strains. Whilst there is no single 'silver bullet' to combat the sealice problem, Benchmark continues to invest in a range of new technologies to tackle the sea lice challenge, including biological control such as lumpfish production and vaccine development".

 

-ENDS-

 

Benchmark Holdings plc

Tel: 020 7920 3150

Malcolm Pye, CEO

Rachel Aninakwah, Communications

Numis

Tel: 020 7260 1000

Michael Meade / Freddie Barnfield (NOMAD)

James Black (Corporate Broking)

Tavistock

Tel: 020 7920 3150

Niall Walsh / Sophie Praill / Simon Hudson

 

 

Notes to Editors:

Benchmark challenges the status quo in aquaculture, agriculture and animal healthcare.

 

Since 2000, Benchmark has consistently worked to build a platform to serve its customers, helping farmers to take control of their biological environment through the combination of genetics, nutrition, health and knowledge services. Through its in-depth knowledge of animal biology Benchmark is able to tackle the key issues in the aquaculture, livestock and companion animal sectors.

 

The Company has proven distribution capabilities in high growth markets and operates internationally with R&D facilities, commercial farms, diagnostic laboratories, manufacturing sites, production facilities and commercial offices across 27 countries in five continents. As at 30 June 2017, Benchmark employed 951 people. 

 

For further information on Benchmark please visit www.benchmarkplc.com

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAPAMRTMBTBBMR
Date   Source Headline
29th Jul 20227:00 amRNSTotal Voting Rights
14th Jul 20227:00 amRNSNotice of Capital Markets Day and Site Visit
1st Jul 202212:08 pmRNSHolding(s) in Company
30th Jun 20227:00 amRNSTotal Voting Rights
16th Jun 20224:41 pmRNSSecond Price Monitoring Extn
16th Jun 20224:36 pmRNSPrice Monitoring Extension
1st Jun 20227:00 amRNSConversion of loan into green loan
31st May 20227:00 amRNSTotal Voting Rights
23rd May 20225:15 pmRNSDirector Dealings
20th May 20221:05 pmRNSDirector Dealings
18th May 20227:00 amRNSSecond Quarter and Interim results
3rd May 20227:00 amRNSMarket Authorisation Update
29th Apr 20222:29 pmRNSTotal Voting Rights
28th Apr 20227:00 amRNSNotice of Q2 and Interim Results
21st Apr 20223:17 pmRNSHolding(s) in Company
31st Mar 20227:00 amRNSTotal Voting Rights
21st Mar 20227:00 amRNSBlock Listing Six Monthly Return
28th Feb 20229:15 amRNSTotal Voting Rights
22nd Feb 20227:00 amRNSQ1 Results
10th Feb 20225:37 pmRNSResult of AGM
7th Feb 20227:00 amRNSNotice of Q1 Results
4th Feb 20224:41 pmRNSSecond Price Monitoring Extn
4th Feb 20224:36 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSTotal Voting Rights
20th Jan 20227:00 amRNSHolding(s) in Company
31st Dec 20217:00 amRNSTotal Voting Rights
24th Dec 20217:00 amRNSHolding(s) in Company
13th Dec 20213:46 pmRNSHolding(s) in Company
10th Dec 20214:17 pmRNSPosting of Annual Report and Notice of AGM
8th Dec 202112:02 pmRNSDIRECTOR SHARE OPTIONS
2nd Dec 20215:58 pmRNSAnnual Report available on website
1st Dec 202110:12 amRNSHolding(s) in Company
1st Dec 202110:02 amRNSTotal Voting Rights
29th Nov 20212:38 pmRNSPCA Dealing
29th Nov 202110:50 amRNSANNOUNCEMENT REGARDING DIRECTOR SUBSCRIPTIONS
29th Nov 20217:01 amRNSPlacing and Appointment of non-Executive Director
29th Nov 20217:00 amRNSQ4 Results
29th Nov 20217:00 amRNSFull Year Results
12th Nov 20217:00 amRNSInvestor Presentation covering Full Year Results
29th Oct 20217:00 amRNSTotal Voting Rights
18th Oct 20217:00 amRNSTrading Statement
30th Sep 20217:00 amRNSTotal Voting Rights
23rd Sep 20217:00 amRNSEnvironmental recognition for CleanTreat®
21st Sep 20217:00 amRNSBlock Listing Six Monthly Return
31st Aug 20217:00 amRNSTotal Voting Rights
25th Aug 20217:00 amRNSEquity Development Investor Webinar
24th Aug 20217:00 amRNSQ3 Results
30th Jul 20217:00 amRNSTotal Voting Rights
15th Jul 20213:00 pmRNSAdoption of MRL for Ectosan Vet in Norway
2nd Jul 20213:20 pmRNSBMK08+CleanTreat and Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.